The Technical Analyst
Nuvalent, Inc. [NUVL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Nuvalent, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.20% $66.86
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 283.56 mill |
| EPS: | -2.17 |
| P/E: | -30.81 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 64.07 mill |
| Avg Daily Volume: | 0.481 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -30.81 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -5.24x |
| Company: PE -30.81 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$5.76 (-91.38%) $-61.10 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 63.39 - 70.34 ( +/- 5.20%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-22 | Shair Matthew | Sell | 14 156 | Class A Common Stock |
| 2024-04-22 | Shair Matthew | Sell | 8 694 | Class A Common Stock |
| 2024-04-22 | Shair Matthew | Sell | 14 650 | Class A Common Stock |
| 2024-04-15 | Shair Matthew | Sell | 25 600 | Class A Common Stock |
| 2024-04-15 | Shair Matthew | Sell | 11 900 | Class A Common Stock |
| INSIDER POWER |
|---|
| -39.49 |
| Last 100 transactions |
| Buy: 784 474 | Sell: 1 684 248 |
Forecast:
16:00 - $66.86
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $66.86
Forecast 2: 16:00 - $66.86
Forecast 3: 16:00 - $66.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $66.86 (1.20% ) |
| Volume | 0.225 mill |
| Avg. Vol. | 0.481 mill |
| % of Avg. Vol | 46.85 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NUVL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $80.73 | N/A | Active |
|---|
NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-08 16:30:00 - Press Release
Nuvalent Presents New Preclinical Data Supporting Profiles Of Her2-selective Inhibitor, Nvl-330, And Ros1-selective Inhibitor, Zidesamtinib, At Aacr Annual Meeting 2024
Preclinical data continue to support nvl-330's broad activity against her2 oncogenic alterations, selectivity over wild-type egfr, and differentiated brain-penetrant profile zidesamtinib shown to be effective at suppressing on-target ros1 resistance mutations in preclinical mutagenesis screens cambridge, mass. , april 8, 2024 /prnewswire/ -- nuvalent, inc. (nasdaq: nuvl), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data for its novel her2-selective inhibitor, nvl-330, and novel ros1-selective inhibitor, zidesamtinib (nvl-520).
2024-03-05 16:52:00 - Press Release
Nuvalent To Present New Preclinical Data On Her2-selective Inhibitor, Nvl-330, And Ros1-selective Inhibitor, Zidesamtinib, At Aacr Annual Meeting 2024
Cambridge, mass., march 5, 2024 /prnewswire/ -- nuvalent, inc. (nasdaq: nuvl), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced upcoming preclinical data poster presentations further characterizing the preclinical profiles of its novel her2-selective inhibitor, nvl-330, and novel ros1-selective inhibitor, zidesamtinib (nvl-520), at the american association for cancer research (aacr) annual meeting 2024 from april 5 – 10 in san diego.
2024-02-27 06:30:00 - Press Release
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones And Reports Fourth Quarter And Full Year 2023 Financial Results
Well-capitalized with operating runway anticipated into 2027 cambridge, mass. , feb. 27, 2024 /prnewswire/ -- nuvalent, inc. (nasdaq: nuvl), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones and reported fourth quarter and full year 2023 financial results.
2024-02-27 06:15:00 - Press Release
Nuvalent Receives U.s. Fda Breakthrough Therapy Designation For Nvl-520
Cambridge, mass. , feb. 27, 2024 /prnewswire/ -- nuvalent, inc. (nasdaq: nuvl), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the u.s. food and drug administration (fda) has granted breakthrough therapy designation (btd) to nvl-520 for the treatment of patients with ros1-positive metastatic non-small cell lung cancer (nsclc) who have been previously treated with two or more ros1 tyrosine kinase inhibitors (tkis).
2024-02-12 06:30:00 - Press Release
Nuvalent Initiates The Phase 2 Portion Of Alkove-1 Clinical Trial For Patients With Alk-positive Nsclc And Other Solid Tumors
Alignment with us food and drug administration on a recommended phase 2 dose for nvl-655 of 150 mg once daily phase 2 designed with registrational intent for tki pre-treated patients with alk-positive nsclc and enables preliminary evaluation in the tki-naÏve setting cambridge, mass. , feb. 12, 2024 /prnewswire/ -- nuvalent, inc. (nasdaq: nuvl), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the initiation of the phase 2 portion of alkove-1, its phase 1/2 clinical trial of nvl-655 for patients with alk-positive non-small cell lung cancer (nsclc) and other solid tumors, following alignment with the us food and drug administration (fda) on a recommended phase 2 dose (rp2d) of 150 mg once daily (qd).
Latest News
2024-03-05 16:52:00 - PRNewsWire
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced upcoming preclinical data poster presentations further characterizing the preclinical profiles of its novel HER2-selective inhibitor, NVL-330, and novel ROS1-selective inhibitor, zidesamtinib (NVL-520), at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5 – 10 in San Diego.
2024-02-26 14:55:47 - Seeking Alpha
Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024
Nuvalent, Inc. expects final results from the phase 1 ARROS-1 study, using NVL-520 for the treatment of patients with ROS-1 positive non-small cell lung cancer, in 2024 at a medical meeting. Final results from the phase 1 ALKOVE-1, using NVL-655 for the treatment of patients with ALK-positive non-small cell lung cancer, expected in 2024 at a medical meeting. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; About 1% to 3% have ROS-1 mutation and 3% to 5% have ALK mutation.
2023-12-21 06:30:00 - PRNewsWire
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 21, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
2023-10-23 02:50:39 - InvestorPlace
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
2023-10-17 18:27:51 - The Motley Fool
Why Nuvalent Stock Tanked on Tuesday
The biotech announced a secondary share flotation. It will sell over 5 million shares of its common stock in a public offering.
2023-10-05 19:13:22 - The Motley Fool
Why Nuvalent Stock Skyrocketed 35% This Week
Nuvalent announced favorable preliminary data from a phase 1 trial indicating its drug NVL-655 was well tolerated with mild adverse events. It's still early, but management is encouraged by the data.
2023-10-05 12:02:39 - Zacks Investment Research
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.
2023-10-05 11:00:43 - Seeking Alpha
Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip
Nuvalent, Inc. stock gained 36% and reached an all-time high of $58 per share yesterday, with a market cap valuation of $3.3bn. The biotech company is focused on developing targeted therapies for cancer patients, with its lead drug candidates showing promising results in treating lung cancer. Data released yesterday from candidate NVL-655 in NSCLC, showing a 65% ORR in patients with ALK+NSCLC, impressed the market.
2023-10-04 16:13:47 - The Motley Fool
Why Nuvalent Stock Was Soaring Wednesday
Nuvalent is a clinical-stage biotech. The company said its therapy showed effectiveness and a strong safety profile in its phase 1/2 trial to treat ALK-positive non-small cell lung cancer.
2023-09-18 06:30:00 - PRNewsWire
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass. , Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 at the 35th AACR-NCI-EORTC (ANE) Symposium taking place October 11-15, 2023, in Boston, Massachusetts.